Share Price and Basic Stock Data
Last Updated: October 27, 2025, 4:33 pm
| PEG Ratio | 0.94 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Bacil Pharma Ltd operates within the pharmaceuticals sector, and its market capitalization currently stands at ₹62.2 Cr with a share price of ₹43.3. Notably, the company reported zero sales across multiple quarters, including Jun 2022 to Jun 2024, indicating a significant challenge in generating revenue. The lack of sales has likely impacted investor sentiment, as reflected in the high price-to-earnings (P/E) ratio of 56.0, which may not align with traditional industry benchmarks. In terms of expenses, Bacil Pharma recorded a total of ₹0.17 Cr in Mar 2023, which has gradually increased to ₹0.25 Cr by Mar 2025. This persistent expenditure without corresponding sales raises questions regarding operational efficiency and strategic direction. The company has also shown sporadic other income, with a notable increase to ₹1.00 Cr in Jun 2025, suggesting potential avenues for revenue generation outside its core operations. However, the overall trend remains concerning, as the absence of consistent sales could hinder long-term sustainability.
Profitability and Efficiency Metrics
Profitability metrics for Bacil Pharma Ltd illustrate a challenging environment, with net profits fluctuating between losses and minor gains. The company recorded a net profit of ₹0.40 Cr for FY 2025, a significant improvement from previous years, where it faced losses, such as ₹-3.86 Cr in FY 2022. Despite this recovery, the operating profit margin (OPM) remains unreported, indicating a lack of clarity on operational efficiency. The return on equity (ROE) for FY 2025 stands at 1.58%, while the return on capital employed (ROCE) is slightly higher at 1.60%. These figures reflect a modest return on investments, especially when compared to industry averages, which typically range higher in a healthy business environment. Additionally, the interest coverage ratio is not applicable, given the company’s negligible borrowings of ₹0.16 Cr. Overall, while Bacil Pharma has shown signs of profitability, its efficiency ratios suggest that improved operational strategies are necessary to enhance profitability sustainably.
Balance Sheet Strength and Financial Ratios
Bacil Pharma’s balance sheet presents a mixed picture of financial health. The company reported total assets of ₹25.61 Cr as of Mar 2025, significantly rising from previous years, which may indicate strategic investments or acquisitions. The reserves have also turned around to ₹11.46 Cr, a notable recovery from the negative reserves in earlier years. The debt-to-equity ratio is exceptionally low at 0.01, indicating minimal leverage and a conservative approach to financing operations. This low level of debt could be seen as a strength, providing the company with financial flexibility. Moreover, the current and quick ratios are remarkably high at 17.64, suggesting excellent liquidity and the ability to meet short-term obligations. However, the enterprise value (EV) to EBITDA ratio is quite high at 138.79, which raises concerns about valuation relative to earnings before interest, taxes, depreciation, and amortization. This could indicate potential overvaluation or inefficiencies in earnings generation.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Bacil Pharma Ltd highlights a significant shift in investor confidence. As of Mar 2025, promoter ownership has drastically reduced to 0.20%, down from 42.67% in previous quarters, indicating a potential exit or dilution of stake by promoters. In contrast, public shareholding has surged to 99.80%, reflecting a growing interest among retail investors. The number of shareholders has also increased to 7,532, suggesting a rising engagement with the company despite its operational challenges. This shift could imply that retail investors are optimistic about the company’s turnaround potential, particularly following the reported net profit in FY 2025. However, the lack of institutional investments, with no Foreign Institutional Investors (FIIs) or Domestic Institutional Investors (DIIs) recorded, may signal a cautious stance from larger investors who typically seek more stability and growth in their portfolios. The heavy reliance on public ownership may lead to volatility in stock performance, particularly if sentiment shifts unfavorably.
Outlook, Risks, and Final Insight
If Bacil Pharma can sustain its recent profitability and leverage its high liquidity to invest in growth initiatives, it may gradually recover from its previous operational setbacks. The shift in shareholder composition indicates potential for increased market confidence, particularly if the company can translate its liquidity into revenue-generating activities. However, significant risks remain, including the ongoing absence of sales, which could undermine investor confidence if not addressed. Additionally, the substantial drop in promoter shareholding raises concerns about the management’s commitment and strategic vision. Should the company fail to establish a robust revenue stream, it may struggle to maintain investor support, particularly among institutional players. Thus, while the recent net profit is a positive indicator, sustained performance will depend on the company’s ability to capitalize on its liquidity and improve operational efficiency, turning the tide towards a more favorable business trajectory.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Bacil Pharma Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 150 Cr. | 119 | 247/84.3 | 34.1 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.96 Cr. | 2.07 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,969 Cr. | 456 | 465/192 | 111 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.6 Cr. | 48.0 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 30.2 Cr. | 20.6 | 29.1/17.0 | 31.5 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,826.62 Cr | 1,181.73 | 50.34 | 194.36 | 0.33% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.05 | 0.04 | 0.04 | 0.09 | 0.03 | 0.04 | 0.05 | 0.06 | 0.04 | 0.07 | 0.06 | 0.07 | 0.11 |
| Operating Profit | -0.05 | -0.04 | -0.04 | -0.09 | -0.03 | -0.04 | -0.05 | -0.06 | -0.04 | -0.07 | -0.06 | -0.07 | -0.11 |
| OPM % | |||||||||||||
| Other Income | 0.07 | 0.04 | 0.00 | 0.01 | 0.05 | 0.03 | 0.03 | 0.02 | 0.01 | 0.56 | 0.00 | 0.09 | 1.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.02 | 0.00 | -0.04 | -0.08 | 0.02 | -0.01 | -0.02 | -0.04 | -0.03 | 0.49 | -0.06 | 0.02 | 0.89 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 24.72% | |
| Net Profit | 0.02 | 0.00 | -0.04 | -0.08 | 0.02 | -0.01 | -0.02 | -0.04 | -0.03 | 0.48 | -0.06 | 0.02 | 0.67 |
| EPS in Rs | 0.03 | 0.00 | -0.07 | -0.14 | 0.03 | -0.02 | -0.03 | -0.07 | -0.05 | 0.81 | -0.10 | 0.01 | 0.47 |
Last Updated: August 19, 2025, 10:45 pm
Below is a detailed analysis of the quarterly data for Bacil Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Expenses, as of Jun 2025, the value is 0.11 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.07 Cr. (Mar 2025) to 0.11 Cr., marking an increase of 0.04 Cr..
- For Operating Profit, as of Jun 2025, the value is -0.11 Cr.. The value appears to be declining and may need further review. It has decreased from -0.07 Cr. (Mar 2025) to -0.11 Cr., marking a decrease of 0.04 Cr..
- For OPM %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Other Income, as of Jun 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.09 Cr. (Mar 2025) to 1.00 Cr., marking an increase of 0.91 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.89 Cr.. The value appears strong and on an upward trend. It has increased from 0.02 Cr. (Mar 2025) to 0.89 Cr., marking an increase of 0.87 Cr..
- For Tax %, as of Jun 2025, the value is 24.72%. The value appears to be increasing, which may not be favorable. It has increased from 0.00% (Mar 2025) to 24.72%, marking an increase of 24.72%.
- For Net Profit, as of Jun 2025, the value is 0.67 Cr.. The value appears strong and on an upward trend. It has increased from 0.02 Cr. (Mar 2025) to 0.67 Cr., marking an increase of 0.65 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.47. The value appears strong and on an upward trend. It has increased from 0.01 (Mar 2025) to 0.47, marking an increase of 0.46.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:50 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.09 | 0.11 | 0.13 | 0.17 | 0.29 | 0.26 | 0.18 | 0.16 | 0.16 | 0.17 | 0.19 | 0.25 | 0.31 |
| Operating Profit | -0.09 | -0.11 | -0.13 | -0.17 | -0.29 | -0.26 | -0.18 | -0.16 | -0.16 | -0.17 | -0.19 | -0.25 | -0.31 |
| OPM % | |||||||||||||
| Other Income | -0.01 | 0.08 | 0.06 | 0.17 | -3.42 | -0.07 | -0.12 | -0.07 | -3.70 | 0.07 | 0.13 | 0.66 | 1.65 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.11 | -0.03 | -0.07 | 0.00 | -3.75 | -0.34 | -0.32 | -0.23 | -3.86 | -0.10 | -0.06 | 0.41 | 1.34 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| Net Profit | -0.11 | -0.03 | -0.07 | 0.00 | -3.75 | -0.34 | -0.32 | -0.24 | -3.86 | -0.10 | -0.06 | 0.40 | 1.11 |
| EPS in Rs | -0.19 | -0.05 | -0.12 | 0.00 | -6.37 | -0.58 | -0.54 | -0.41 | -6.55 | -0.17 | -0.10 | 0.28 | 1.19 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 72.73% | -133.33% | 100.00% | 90.93% | 5.88% | 25.00% | -1508.33% | 97.41% | 40.00% | 766.67% |
| Change in YoY Net Profit Growth (%) | 0.00% | -206.06% | 233.33% | -9.07% | -85.05% | 19.12% | -1533.33% | 1605.74% | -57.41% | 726.67% |
Bacil Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 31% |
| 5 Years: | 54% |
| 3 Years: | 82% |
| TTM: | 1210% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 64% |
| 3 Years: | 102% |
| 1 Year: | 69% |
| Return on Equity | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | -1% |
| 3 Years: | 1% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 2:31 pm
Balance Sheet
Last Updated: October 10, 2025, 3:34 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 6.53 | 13.97 |
| Reserves | -0.03 | -0.06 | -0.13 | -0.09 | -4.29 | -4.62 | -5.14 | -5.14 | -5.30 | -5.43 | -5.31 | 11.46 |
| Borrowings | 0.08 | 0.14 | 0.27 | 0.31 | 0.00 | 0.10 | 0.17 | 0.18 | 0.03 | 0.02 | 0.10 | 0.16 |
| Other Liabilities | 0.01 | 0.02 | 0.02 | 0.02 | 2.51 | 2.55 | 2.55 | 2.52 | 0.01 | 0.01 | 0.01 | 0.02 |
| Total Liabilities | 6.59 | 6.63 | 6.69 | 6.77 | 4.75 | 4.56 | 4.11 | 4.09 | 1.27 | 1.13 | 1.33 | 25.61 |
| Fixed Assets | 0.01 | 0.01 | 5.25 | 5.94 | 2.53 | 2.53 | 2.52 | 2.51 | 0.01 | 0.01 | 0.01 | 0.00 |
| CWIP | 5.80 | 5.88 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.25 | 0.51 | 0.51 | 0.54 | 1.15 | 0.96 | 0.43 | 0.37 | 0.31 | 0.43 | 0.61 | 21.36 |
| Other Assets | 0.53 | 0.23 | 0.93 | 0.29 | 1.07 | 1.07 | 1.16 | 1.21 | 0.95 | 0.69 | 0.71 | 4.25 |
| Total Assets | 6.59 | 6.63 | 6.69 | 6.77 | 4.75 | 4.56 | 4.11 | 4.09 | 1.27 | 1.13 | 1.33 | 25.61 |
Below is a detailed analysis of the balance sheet data for Bacil Pharma Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 13.97 Cr.. The value appears strong and on an upward trend. It has increased from 6.53 Cr. (Mar 2024) to 13.97 Cr., marking an increase of 7.44 Cr..
- For Reserves, as of Mar 2025, the value is 11.46 Cr.. The value appears strong and on an upward trend. It has increased from -5.31 Cr. (Mar 2024) to 11.46 Cr., marking an increase of 16.77 Cr..
- For Borrowings, as of Mar 2025, the value is 0.16 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 0.10 Cr. (Mar 2024) to 0.16 Cr., marking an increase of 0.06 Cr..
- For Other Liabilities, as of Mar 2025, the value is 0.02 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.01 Cr. (Mar 2024) to 0.02 Cr., marking an increase of 0.01 Cr..
- For Total Liabilities, as of Mar 2025, the value is 25.61 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.33 Cr. (Mar 2024) to 25.61 Cr., marking an increase of 24.28 Cr..
- For Fixed Assets, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.01 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 0.01 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 21.36 Cr.. The value appears strong and on an upward trend. It has increased from 0.61 Cr. (Mar 2024) to 21.36 Cr., marking an increase of 20.75 Cr..
- For Other Assets, as of Mar 2025, the value is 4.25 Cr.. The value appears strong and on an upward trend. It has increased from 0.71 Cr. (Mar 2024) to 4.25 Cr., marking an increase of 3.54 Cr..
- For Total Assets, as of Mar 2025, the value is 25.61 Cr.. The value appears strong and on an upward trend. It has increased from 1.33 Cr. (Mar 2024) to 25.61 Cr., marking an increase of 24.28 Cr..
Notably, the Reserves (11.46 Cr.) exceed the Borrowings (0.16 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.17 | -0.25 | -0.40 | -0.48 | -0.29 | -0.36 | -0.35 | -0.34 | -0.19 | -0.19 | -0.29 | -0.41 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | ||||||||||||
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | ||||||||||||
| Working Capital Days | ||||||||||||
| ROCE % | -0.61% | -0.45% | -1.05% | -1.49% | -6.01% | -8.47% | -2.80% | -5.75% | -7.07% | -12.61% | -13.11% | -0.97% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.64 | -0.10 | -0.17 | -6.55 | -0.41 |
| Diluted EPS (Rs.) | 0.64 | -0.10 | -0.17 | -6.55 | -0.41 |
| Cash EPS (Rs.) | 0.28 | -0.08 | -0.15 | -5.91 | -0.35 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 18.20 | 1.86 | 1.68 | 1.88 | 2.13 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 18.20 | 1.86 | 1.68 | 1.88 | 2.13 |
| PBDIT / Share (Rs.) | 0.29 | -0.08 | -0.15 | -5.91 | -0.35 |
| PBIT / Share (Rs.) | 0.29 | -0.09 | -0.15 | -5.91 | -0.36 |
| PBT / Share (Rs.) | 0.29 | -0.09 | -0.15 | -5.91 | -0.36 |
| Net Profit / Share (Rs.) | 0.28 | -0.09 | -0.15 | -5.91 | -0.36 |
| Return on Networth / Equity (%) | 1.58 | -4.85 | -9.26 | -315.24 | -17.19 |
| Return on Capital Employeed (%) | 1.60 | -4.86 | -9.26 | -315.26 | -17.22 |
| Return On Assets (%) | 1.57 | -4.44 | -9.03 | -303.54 | -5.85 |
| Total Debt / Equity (X) | 0.01 | 0.08 | 0.01 | 0.02 | 0.12 |
| Current Ratio (X) | 17.64 | 0.46 | 8.19 | 10.63 | 1.04 |
| Quick Ratio (X) | 17.64 | 0.46 | 8.19 | 10.63 | 1.04 |
| Enterprise Value (Cr.) | 22.33 | 9.61 | 3.57 | 3.54 | 2.11 |
| EV / EBITDA (X) | 138.79 | -168.53 | -35.97 | -0.91 | -9.00 |
| Price / BV (X) | 2.33 | 7.87 | 3.25 | 3.06 | 1.46 |
| EarningsYield | 0.01 | -0.01 | -0.02 | -1.03 | -0.11 |
After reviewing the key financial ratios for Bacil Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 5. It has increased from -0.10 (Mar 24) to 0.64, marking an increase of 0.74.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 5. It has increased from -0.10 (Mar 24) to 0.64, marking an increase of 0.74.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 3. It has increased from -0.08 (Mar 24) to 0.28, marking an increase of 0.36.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 18.20. It has increased from 1.86 (Mar 24) to 18.20, marking an increase of 16.34.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 18.20. It has increased from 1.86 (Mar 24) to 18.20, marking an increase of 16.34.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 0.29. This value is below the healthy minimum of 2. It has increased from -0.08 (Mar 24) to 0.29, marking an increase of 0.37.
- For PBIT / Share (Rs.), as of Mar 25, the value is 0.29. This value is within the healthy range. It has increased from -0.09 (Mar 24) to 0.29, marking an increase of 0.38.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.29. This value is within the healthy range. It has increased from -0.09 (Mar 24) to 0.29, marking an increase of 0.38.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 2. It has increased from -0.09 (Mar 24) to 0.28, marking an increase of 0.37.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.58. This value is below the healthy minimum of 15. It has increased from -4.85 (Mar 24) to 1.58, marking an increase of 6.43.
- For Return on Capital Employeed (%), as of Mar 25, the value is 1.60. This value is below the healthy minimum of 10. It has increased from -4.86 (Mar 24) to 1.60, marking an increase of 6.46.
- For Return On Assets (%), as of Mar 25, the value is 1.57. This value is below the healthy minimum of 5. It has increased from -4.44 (Mar 24) to 1.57, marking an increase of 6.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. It has decreased from 0.08 (Mar 24) to 0.01, marking a decrease of 0.07.
- For Current Ratio (X), as of Mar 25, the value is 17.64. This value exceeds the healthy maximum of 3. It has increased from 0.46 (Mar 24) to 17.64, marking an increase of 17.18.
- For Quick Ratio (X), as of Mar 25, the value is 17.64. This value exceeds the healthy maximum of 2. It has increased from 0.46 (Mar 24) to 17.64, marking an increase of 17.18.
- For Enterprise Value (Cr.), as of Mar 25, the value is 22.33. It has increased from 9.61 (Mar 24) to 22.33, marking an increase of 12.72.
- For EV / EBITDA (X), as of Mar 25, the value is 138.79. This value exceeds the healthy maximum of 15. It has increased from -168.53 (Mar 24) to 138.79, marking an increase of 307.32.
- For Price / BV (X), as of Mar 25, the value is 2.33. This value is within the healthy range. It has decreased from 7.87 (Mar 24) to 2.33, marking a decrease of 5.54.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from -0.01 (Mar 24) to 0.01, marking an increase of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bacil Pharma Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 1.6% (Industry Average ROCE: 16.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.58% (Industry Average ROE: 14.47%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 17.64
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 51 (Industry average Stock P/E: 41.82)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 71, Laxmi Building, Mumbai Maharashtra 400001 | info@bacilpharma.com http://www.bacilpharma.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Shirish Shetty | Ind. Non-Executive Director |
| Mr. Lalit Jain | Ind. Non-Executive Director |
| Mr. Prakash Shah | Director |
FAQ
What is the intrinsic value of Bacil Pharma Ltd?
Bacil Pharma Ltd's intrinsic value (as of 27 October 2025) is 7.22 which is 81.68% lower the current market price of 39.40, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 56.6 Cr. market cap, FY2025-2026 high/low of 62.6/31.6, reserves of ₹11.46 Cr, and liabilities of 25.61 Cr.
What is the Market Cap of Bacil Pharma Ltd?
The Market Cap of Bacil Pharma Ltd is 56.6 Cr..
What is the current Stock Price of Bacil Pharma Ltd as on 27 October 2025?
The current stock price of Bacil Pharma Ltd as on 27 October 2025 is 39.4.
What is the High / Low of Bacil Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Bacil Pharma Ltd stocks is 62.6/31.6.
What is the Stock P/E of Bacil Pharma Ltd?
The Stock P/E of Bacil Pharma Ltd is 51.0.
What is the Book Value of Bacil Pharma Ltd?
The Book Value of Bacil Pharma Ltd is 17.7.
What is the Dividend Yield of Bacil Pharma Ltd?
The Dividend Yield of Bacil Pharma Ltd is 0.00 %.
What is the ROCE of Bacil Pharma Ltd?
The ROCE of Bacil Pharma Ltd is 0.97 %.
What is the ROE of Bacil Pharma Ltd?
The ROE of Bacil Pharma Ltd is 0.98 %.
What is the Face Value of Bacil Pharma Ltd?
The Face Value of Bacil Pharma Ltd is 10.0.